

## Supplementary Information

# Synthesis and Biological Evaluation of Lipophilic Nucleoside Analogues as Inhibitors of Aminoacyl-tRNA Synthetases

By Manesh Nautiyal<sup>1</sup>, Bharat Gadakh<sup>1</sup>, Steff De Graef<sup>2</sup>, Luping Pang<sup>1, 2</sup>, Masroor Khan<sup>1</sup>, Yi Xun<sup>1</sup>, Jef Rozenski<sup>1</sup>, Arthur Van Aerschot<sup>1,\*</sup>.

<sup>1</sup> Medicinal Chemistry, Rega Institute for Medical Research, Herestraat 49 box 1041, B-3000 Leuven, Belgium

<sup>2</sup> Laboratory for Biocrystallography, Department of Pharmaceutical and Pharmacological Sciences, Herestraat 49 box 822, B-3000 Leuven, Belgium

\* To whom correspondence should be addressed. Tel: +32 16 37 26 24; Fax: +32 16 3 37340; Email: [arthur.vanaerschot@kuleuven.be](mailto:arthur.vanaerschot@kuleuven.be)

## Contents


|                                                                         |    |
|-------------------------------------------------------------------------|----|
| Supplementary reaction scheme S1.....                                   | 1  |
| C6 purine derivatives - intermediate & final compounds - NMR & MS ..... | 3  |
| Prodrugs intermediate & final compounds - NMR & MS.....                 | 32 |

## Supplementary reaction scheme S1.

Following **reaction scheme 1**, the plan was to make a general scaffold (**5**) where various substitutions could be introduced using **reaction (iv)**. This reaction scheme proved to be useful for the introduction of N-substituted aliphatic sidechains, albeit with low yields due to degradation of the scaffold (due to the cumulative negative effect of base and high temperature). Unfortunately,


nucleophilic substitution did not work out for the less nucleophilic anilines. Different base catalysts substituting for potassium carbonate like DIPEA and DMAP were also tried combined with heating but to no avail.

Initially proposed plan for the synthesis of alkylated compounds: -




**Supplementary reaction scheme S1. Reagents and conditions:** (i) Acetone, DMP, PTSA, RT, overnight, rt; (ii) (a) CSI, HCOOH, 0 °C, 15 min; (b) ACN, 4-6h, rt; (c) DMA, overnight, rt; (iii) DBU, Boc-Ile-Osu, DMF, overnight, rt; (iv) K<sub>2</sub>CO<sub>3</sub>, R-NH<sub>2</sub>, DMF, 80 °C, overnight; (v) TFA/H<sub>2</sub>O (1:1 v/v), 3 hours, RT.

# C6 purine derivatives - intermediate & final compounds - NMR & MS



Exact Mass: 326.0782



2, 3'-isopropylidene 6-chloropurine riboside (2)



43467  
MAS 06


accurate mass


ES+  
01-Mar-2017



Exact Mass: 321.1437

2',3'-isopropylidene-N6-(methyl)-adenosine (3a)







43803  
MAS 018[1]

accurate mass



ES+  
28-Mar-2017







Exact Mass: 419.2533


2',3'-isopropylidene-N6-(octyl)-adenosine (3b)





Exact Mass: 475.3159



2',3'-isopropylidene-N6-(dodeceyl)-adenosine (3c)



49234  
MN 3C

accurate mass

ES+  
14-Mar-2019




Exact Mass: 559.4098


2',3'-isopropylidene-N6-(octadecyl)-adenosine (3d)

accurate mass

ES+  
14-Mar-2019










Exact Mass: 383.1594



2',3'-isopropylidene-N6-(phenyl)-adenosine (3e)






Exact Mass: 405.0510



2', 3'-isopropylidene-5'-O-sulfamoyl-6-chloropurine riboside (3f)





Exact Mass: 400.1165


2',3'-isopropylidene-5'-O-sulfamoyl-N6-methyl-adenosine (4a)



43869  
MN MET SO2


accurate mass



ES+  
03-Apr-2017




Exact Mass: 498.2261

2',3'-isopropylidene-5'-O-sulfamoyl-N6-octyl-adenosine (4b)










Exact Mass: 554.2887



# 2',3'-isopropylidene-5'-O-sulfamoyl-N6-dodecyl-adenosine (4c)





Exact Mass: 638.3826



2',3'-isopropylidene-5'-O-sulfamoyl-N6-octadecyl-adenosine (4d)



43963  
MAS 23B


accurate mass

ES+  
10-Apr-2017






Exact Mass: 462.1322

2',3'-isopropylidene-5'-O-sulfamoyl-N6-phenyl-adenosine (4e)












Exact Mass: 401.1005


2', 3'-isopropylidene-5'-O-sulfamoyl-6-O-methyl-purine riboside (4f)






Exact Mass: 613.2530


2',3'-isopropylidene-5'-O-(N-(N $\alpha$ -Boc-L-isoleucyl))-sulfamoyl-N6-methyl-adenosine (5a)






Exact Mass: 711.3625

2',3'-isopropylidene-5'-O-(N-(N $\alpha$ -Boc-L-isoleucyl))-sulfamoyl-N6-octyl-adenosine (5b)







Exact Mass: 767.4251

N6-dodecyl-adenosine (5c)


2',3'-isopropylidene-5'-O-(N-(N $\alpha$ -Boc-L-isoleucyl))-sulfamoyl-






Exact Mass: 851.5190

2',3'-isopropylidene-5'-O-(N-(N $\alpha$ -Boc-L-isoleucyl))-sulfamoyl-N6-octadecyl-adenosine (5d)





Exact Mass: 675.2686


sulfamoyl-N6-phenyl-adenosine (5e)


2',3'-isopropylidene-5'-O-(N-(N $\alpha$ -Boc-L-isoleucyl))-

43864  
MAS 20[A50]

accurate mass



ES-  
03-Apr-2017







Exact Mass: 473.1693


5'-O-(N-L-isoleucyl)-sulfamoyl-N<sup>6</sup>-methyl-adenosine (6a)








5'-O-(N-L-isoleucyl)-sulfamoyl-N6-octyl-adenosine (6b)







44020  
MAS OCTF

accurate mass



ES-  
14-Apr-2017






Exact Mass: 627.3414


# 5'-O-(N-L-isoleucyl)-sulfamoyl-N6-dodecyl-adenosine (6c)





Exact Mass: 711.4353


# 5'-O-(N-L-isoleucyl)-sulfamoyl-N6-octadecyl-adenosine (6d)




44366  
MAS 26[HC18]

accurate mass



ES-  
24-May-2017





Exact Mass: 535.1849



5'-O-(N-L-isoleucyl)-sulfamoyl-N<sup>6</sup>-phenyl-adenosine (6e)




44046  
MAS 21[3FLC]


accurate mass

ES-  
21-Apr-2017



5'-O-(N-L-isoleucyl)-sulfamoyl-6-O-methyl-purine riboside (6f)







44169  
MAS 31[OME]

accurate mass


ES-  
04-May-2017



## Prodrugs intermediate & final compounds - NMR & MS



TBDMSO 2',3'-di-O-TBDMS 5'-O-[N-(N-Boc)leucyl]sulfamoyl  
adenosine (11)








45820  
YX 19 COLUMN


accurate mass

ES-  
16-Nov-2017



TBDMSO OTBDMS 2',3'-di-O-TBDMS-5'-O-(N-leucyl)sulfamoyl adenosine (12)







46830  
MN YX 20

accurate mass



ES-  
09-Apr-2018





2',3'-di-O-TBDMS-5'-O-[N $\alpha$ -(p-nitrobenzyloxycarbonyl)leucyl]sulfamoyl



adenosine (13)




45861  
YX 21


accurate mass

ES-  
23-Nov-2017



5'-O-[N $\alpha$ -(p-nitrobenzyloxycarbonyl)leucyl]sulfamoyl adenosine (14)







46439  
MN YX 31



accurate mass


ES-  
15-Feb-2018






*p*-acetoxybenzyloxycarbonylchloride (16)








sulfamoyl adenosine (17)

2',3'-di-*O*-TBDMS-5'-*O*-[*N*<sup>α</sup>-(*p*-acetoxybenzyloxycarbonyl)leucyl]





5'-O-[N $\alpha$ -(p-acetyloxybenzyloxycarbonyl)leucyl]sulfamoyl adenosine (18).





46697A  
MN 281

accurate mass

ES+  
16-Mar-2018

